Physician profile
Harrup Kaur
NPI 1427038074
$4,680.25
in general payments reported to CMS, 2019-2025
24 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $2,311 · 2021: $397 · 2022: $306 · 2023: $178 · 2024: $326 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Konan Medical USA, INC. | $2,195.00 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $394.55 | 2019-2021 | |
| Sight Sciences, INC. | $295.20 | 2021-2025 | Omni Surgical System |
| Glaukos Corporation | $256.60 | 2019-2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $197.11 | 2019-2022 | |
| Allergan, INC. | $195.34 | 2019-2022 | |
| Alcon Vision LLC | $156.64 | 2019-2025 | Clareon, Tryptyr, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $135.63 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $124.60 | 2019 | |
| Oyster Point Pharma, INC. | $91.41 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $77.78 | 2022-2024 | Vyzulta, Miebo |
| Ivantis, INC | $74.62 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $60.08 | 2023-2025 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator |
| Biotissue Holdings INC. | $56.48 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $47.84 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $46.17 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $40.97 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $40.63 | 2019 | |
| Rxsight INC | $38.88 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Amgen INC. | $25.23 | 2025 | Tepezza |
| Abbvie INC. | $24.56 | 2022 | |
| Dompe US, INC. | $24.01 | 2025 | Oxervate |
| Akorn, INC. | $16.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrup Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.